Lucid Diagnostics Inc. Common Stock (LUCD)
Lucid Diagnostics Inc. is a healthcare company focused on early detection and diagnosis of gastrointestinal cancers. Through its proprietary technology and testing methods, it aims to improve patient outcomes by providing non-invasive, accurate diagnostic solutions for conditions such as esophageal and other gastrointestinal cancers.
Company News
Lucid Diagnostics, a cancer prevention medical diagnostics company, announced plans for a public stock offering to support working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced the closing on October 18, 2021 of its initial public offering (the “Offering”) of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.